Science brief
From Galactic Tilts to Vaccine Breakthroughs
British researchers solve a long-standing brain paradox, launch a world-first Ebola trial, and map the Milky Way's ancient tilt.
Science
Cambridge scientists have mapped the dual-action brain switches of GIP obesity drugs — paving the way for highly targeted weight-loss treatments with fewer gastrointestinal side effects.
BackgroundObesity treatments like Mounjaro and MariTide target gastric inhibitory polypeptide (GIP) receptors alongside GLP-1 pathways to induce weight loss. However, scientists have long been puzzled by the contradictory biology where opposing drug actions both successfully suppress appetite.
- The Cambridge team discovered that the GIP receptor acts as a localized switch, functioning differently depending on its exact location in the brain, which explains the contradictory findings.
- Stimulating the GIP receptor in the brainstem suppresses appetite, while blocking the exact same receptor in the hypothalamus achieves the same weight loss outcome, showing that anatomical targeting is key.
- The findings provide a clear roadmap for pharmaceutical developers to design highly targeted treatments that maximize weight loss while reducing gastrointestinal side effects, which could improve patient compliance.
Science
Durham astronomers have shown that the Milky Way underwent a massive 90-degree disk tilt — solving a long-standing mystery about the rotation of our galaxy's oldest stars.
BackgroundThe outer halo of the Milky Way contains ancient stars that rotate unusually slowly compared to the rapid spin of the main stellar disk. Astronomers have struggled to explain this rotational mismatch using standard models of galactic formation.
- Using the 'Auriga' supercomputer simulations, researchers modeled the impact of a head-on collision with the massive dwarf galaxy Gaia-Sausage-Enceladus, showing how the massive impact reshaped our galaxy.
- The simulations showed the collision triggered a gradual galactic tilt that took between 150 million and 2 billion years to complete, challenging the idea that galactic orientations remain stable.
- The findings demonstrate that early cosmic mergers can radically reorient entire galaxies, reshaping our understanding of the Milky Way's structural history and the behaviour of its oldest stellar clusters.
Science
Oxford's vaccine platform has transitioned from concept to human trials in eight weeks — potentially delivering the first global protection against the deadly Bundibugyo Ebola strain.
BackgroundWhile licensed vaccines exist for the common Zaire ebolavirus strain, there are currently no approved protections against the Bundibugyo strain. This clinical gap has left populations highly vulnerable during active outbreaks across Central Africa.
- The Phase I trial, backed by a £6.6M ($8.6M) grant from the Coalition for Epidemic Preparedness Innovations, will test safety in 50 healthy UK adults, marking a crucial step toward approval.
- The Serum Institute of India has already partnered to manufacture and stockpile 620,000 doses in advance, ensuring rapid deployment across African outbreak zones if clinical trials succeed.
- The rapid eight-week transition from concept to clinical trial highlights the maturity of Oxford's pandemic response infrastructure, potentially setting a new speed standard for future global health emergencies.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.